Guberina, Maja
Darwiche, Kaid
Hautzel, Hubertus
Ploenes, Till
Pöttgen, Christoph
Guberina, Nika
Herrmann, Ken
Umutlu, Lale
Wetter, Axel
Theegarten, Dirk
Aigner, Clemens
Eberhardt, Wilfried Ernst Erich
Schuler, Martin
Karpf-Wissel, Rüdiger
Stuschke, Martin
Funding for this research was provided by:
Projekt DEAL
Article History
Received: 23 September 2020
Accepted: 17 January 2021
First Online: 5 February 2021
Declarations
:
: The Ethics Committee of the Medical Faculty of the University Duisburg-Essen approved the study (19-9056-BO).
: <b>MD Dr. med. Guberina M</b><sup><b>1</b></sup><b>, PD MD Dr. med. Guberina N</b><sup><b>1</b></sup><b>; Prof. MD. Dr. med. Umutlu L</b><sup><b>6</b></sup><b>, Prof. MD. Dr. med. Wetter A</b><sup><b>6</b></sup><b>: PD MD Dr. med. Ploenes T</b><sup><b>5</b></sup><b>; PD MD Dr. med. Hautzel H</b><sup><b>3, 4</b></sup><b>; Prof. MD. Dr. med. Theegarten D</b><sup><b>7</b></sup><b>, Prof. MD. Dr. med. Aigner C</b><sup><b>5</b></sup><b>; MD Dr. med. Karpf-Wissel R</b><sup><b>2</b></sup>; There are no relationships/conditions/circumstances that present a potential conflict of interest. All authors declare that they have no conflict of interest.<b>Prof. MD. Dr. med. Darwiche K</b><sup><b>2</b></sup><b>:</b> KD received travel grants from Olympus and Boston Scientific. There are no relationships/conditions/circumstances that present a potential conflict of interest<b>Prof. MD. Dr. med. Pöttgen C</b><sup><b>1</b></sup><b>:</b> Prof. Dr. Pöttgen reports personal fees from Roche Pharma, personal fees from Boehringer Ingelheim, personal fees from AstraZeneca, outside the submitted work. There are no relationships/conditions/circumstances that present a potential conflict of interest<b>Prof. MD. Dr. med. Herrmann K</b><sup><b>3,4</b></sup><b>:</b> Prof. Dr. Herrmann reports personal fees from Bayer, other from Sofie Biosciences, personal fees from SIRTEX, non-financial support from ABX, personal fees from Adacap, personal fees from Curium, personal fees from Endocyte, grants and personal fees from BTG, personal fees from IPSEN, personal fees from Siemens Healthineers, personal fees from GE Healthcare, personal fees from Amgen, outside the submitted work. There are no relationships/conditions/circumstances that present a potential conflict of interest<b>PD MD. Dr. med. Eberhardt W</b><sup><b>8, 9</b></sup><b>:</b>Honoraria (Advisory board function) AstraZeneca, BMS, Roche, MSD, Pfizer, Boehringer, Takeda, Eli Lilly, Bayer, CelgeneHonoraria (educational lectures) BMS, MSD AstraZeneca, Roche, Novartis, Pfizer, Boehringer, Takeda, Abbvie, Celgene, Eli LillyResearch grant Eli Lilly, BMS, AstraZenecaOther noneThe author declares that no competing interests exist.<b>Prof. MD. Dr. med. Schuler M</b><sup><b>4, 8, 9</b></sup><b>:</b> Consultant (compensated): AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Novartis, Roche. Honoraries for CME presentations: Abbvie, Alexion, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Lilly, MSD, Novartis, Pierre Fabre.Research funding to institution: AstraZeneca, Boehringer Ingelheim, Bristol-Myers, Squibb, NovartisMS confirms that the above mentioned funding source was not involved in the study design or materials used, neither in the collection, analysis, and interpretation of data nor in the writing of the paper.<b>Prof. MD. Dr. med. Stuschke M</b><sup><b>1, 4</b></sup><b>:</b> Honoraria (Advisory board function) AstraZeneca, Bristol-Myers Squibb, Sanofi-Aventis, Janssen-Cilag Research funding to institution by AstraZeneca in 2019 and 2020. Prof. Dr. Martin Stuschke confirms that the above mentioned funding source was not involved in the study design or materials used, neither in the collection, analysis, and interpretation of data nor in the writing of the paper.